antibodies
Autoantibodies May Cause Neurological Symptoms in Long COVID
Autoantibodies Against Nervous System Proteins Identified in Post-COVID Syndrome
Type I Interferons Enhance Antibody Responses to Influenza Vaccination
The IL-21/IL-12 Pathway Also Enhances Antibody Production Independently of Type I Interferons
Bone Marrow Plasma Cells Are a Source of Autoantibodies to Interferon-Gamma in Adult-Onset Immunodeficiency
Why Rituximab Does Not Eliminate Autoantibodies in AOID
Autoantibodies to Interferon Alpha in Patients With Antibody Deficiency
Autoantibodies Are Rare and Do Not Affect Coronavirus Vaccination
Autoantibodies to Type I Interferons – A Risk Factor for Fatal Avian Influenza H5N1
A Case of Pneumonia in a 71-Year-Old Man
Vaccine Targeting IgE
IgE-K Induces Neutralizing Antibodies Similar to Omalizumab
How to Protect a Newborn: Vaccination Before and After Birth
Antibody Transfer Before and After Delivery
Naïve Antibodies Provide Protection Against H5Nx Influenza
Naïve B Cells Recognize Hemagglutinin of Avian Influenza
Impaired Tolerance of Self-Tissues Leads to Autoantibodies Against IFN-I
Autoantibodies against type I interferons (IFN-I) increase susceptibility to severe infections
Rejuvenation of the Immune System: A New Method to Combat Age-Related Immunity Decline
Altering Stem Cell Balance to Combat Aging of the Immune System
Autoantibodies to Interferons Are Not Associated with Chronic Fatigue after COVID-19
Only 1.6% of patients with post-COVID syndrome had autoantibodies to IFN-β
Autoantibodies to Type I Interferons in COVID-19 Patients
Autoantibodies to tissues, immune cells and interferons complicate the course of COVID-19
Antibody-Free Protection: The Effectiveness of COVID-19 Vaccination in Patients with B-Cell Deficiency
Enhanced T-cell responses with B-cell deficiency reduce the risk of severe COVID-19 by 5-fold
Protection Against Omicron: New Vaccines on the Horizon
The World Health Organization has recommended a monovalent vaccine based on the Kraken strain, a subvariant of Omicron
Coronavirus Pyrola: Do Vaccines and Previous Infection Protect Against Other Strains?
Mutations in the Spike Protein Help Pyrola Evade Immune Protection
Indigenous Peoples in Australia More Severely Ill COVID-19
The reason for the weak antibody response is chronic diseases
IgM Antibodies Protect Against Delta and Omicron Strains
IgM antibodies derived from memory B cells neutralize a wide range of coronavirus strains
Post-Vaccination and Natural COVID-19 Antibodies: Which Protect Better?
S-protein in a closed state as the basis of future vaccines
Common Cold Immunity Protects Children From COVID-19
Protein S2 – a promising basis for future coronavirus vaccines
How Long Do Antibodies Persist After COVID-19
After natural SARS-CoV-2, protection against reinfection persists for about two years
What Level of Neutralizing Antibodies Protects Against COVID-19
Antibody titers predict the protective efficacy of vaccines
COVID-19 Symptoms Depend on The Infecting Dose
SARS-CoV-2 dose affects seroconversion and fever
The dominant role of IgA antibodies in the early stage of COVID-19
Most of the IgA is in the mucous membranes, the entrance gate of the coronavirus
Immunological memory for SARS-CoV-2. Five components of the immune response
How coronavirus immunity is formed and how long it lasts. Is immune memory produced and stored for how long in mild and asymptomatic COVID-19
Natural and Post-Vaccination COVID-19 Antibodies: What Is Most Important
Protective level of antibodies to SARS-CoV-2: when it is produced, what it depends on, and how much is stored
Herd immunity to COVID-19
How do cross-reactive memory T cells affect herd immunity to SARS-CoV-2
A way to successful vaccination
Зачем нужны вакцины. Как они работают. Что повышает их эффективность
Russian microbiologists have isolated antibodies that block the reproduction of SARS-CoV-2
Single sorting of B-lymphocytes will increase vaccines safety and make COVID-19 treatment more effective.